Colosimo et al. 50M Metastatic Renal Carcinoma

by Benny | Apr 21, 2021

MultiHance® 9 Image Library 9 Colosimo et al. 50M Metastatic Renal Carcinoma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.50-year-old man with metastatic...

Colosimo et al. 52F Primary Glioma

by Benny | Apr 21, 2021

MultiHance® 9 Image Library 9 Colosimo et al. 52F Primary Glioma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL Improves Visualization and Enhancement of Lesions vs. Dotarem® (gadoterate meglumine)1 Colosimo et al.52-year-old woman with primary glioma These...

Seidl et al. 48F with Non-Hodgkins Lymphoma

by Eric | Apr 20, 2021

MultiHance® 9 Image Library 9 Seidl et al. 48F with Non-Hodgkins Lymphoma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist® (gadobutrol)1 The MERIT StudySeidl et al.48-year-old woman with non-Hodgkins lymphoma These are representative images from...

Seidl et al. 60F with Lung Cancer

by Eric | Apr 18, 2021

MultiHance® 9 Image Library 9 Seidl et al. 60F with Lung Cancer MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist® (gadobutrol)1 The MERIT StudySeidl et al.60-year-old woman with lung cancer These are representative images from reference studies;...

Vaneckova et al. 62F Lung Adenocarcinoma

by Eric | Apr 17, 2021

MultiHance® 9 Image Library 9 Vaneckova et al. 62F Lung Adenocarcinoma MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL vs. Dotarem® (gadoterate meglumine)1 BENEFIT studyVaneckova et al.62-year-old woman with lung adenocarcinoma These are representative...